← All indications
Osteogenesis Imperfecta
COLLAGEN DISEASES characterized by brittle, osteoporotic, and easily fractured bones. It may also present with blue sclerae, loose joints, and imperfect dentin formation. Most types are autosomal dominant and are associated with mutations in COLLAGEN TYPE I.
Drugs by status
Approved for this indication (2)
Phase 4 trials (5)
Phase 3 trials (4)
Phase 2 trials (4)
Phase 1 trials (7)
Organizations
Organization Involved with Phase 4 Indications (17)
- Eli Lilly
- Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- Rockefeller University
- Baylor University
- Cornell University
- Indiana University
- NHS Lothian
- Northwell Health
- Oregon Health and Science University
- Shriners Hospitals for Children
- University of Edinburgh
- Tsinghua University
- National Natural Science Foundation of China
- Osteogenesis Imperfecta Foundation
- The New York Community Trust
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (14)
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (3)